drugset / Trial / NCT04775745
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecule inhibitor.
Timeline
- Start
- 2021-07-19
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rocbrutinib | Small molecule | 100 mg | Oral |
| Subject | Rocbrutinib | Small molecule | 150 mg | Oral |
| Subject | Rocbrutinib | Small molecule | 225 mg | Oral |
| Subject | Rocbrutinib | Small molecule | 300 mg | Oral |
| Subject | Rocbrutinib | Small molecule | 450 mg | Oral |
| Subject | Rocbrutinib | Small molecule | 600 mg | Oral |
| Subject | Rocbrutinib | Small molecule | 800 mg | Oral |
| Subject | Rocbrutinib | Small molecule | 1000 mg | Oral |